Pharmaceuticals

BioDuro-Sundia Wins Life Sciences Review Top 10 BPO Award

IRVINE, Calif., April 4, 2023 /PRNewswire/ -- Life Sciences Review magazine recognizes BioDuro-Sundia as top 10 Business Process Outsourcing (BPO). BioDuro-Sundia earned this award for its high-quality service and cutting-edge technology, as well as its integrated contract research, development a...

2023-04-04 08:30 4420

Lynk Pharmaceuticals Announces Positive Results for LNK01003 in Phase I Trial in Healthy Subjects

HANGZHOU, China, April 4, 2023 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. (hereinafter referred to as 'Lynk Pharmaceuticals'), an innovative clinical stage company, announced that it has recently completed phase I trials in healthy subjects inChina for its self-developed innovative intestina...

2023-04-04 08:00 4763

GC Cell and New Management Embarking on a New Chapter

* Securing future growth engine by scouting global talents; AGM resolved new CEOJames Park and CTO Ho-won Kim as internal directors * Setting business goals focusing on change and growth * Proposing a new corporate vision of "Global Creator of Cell & Gene Therapy" YONGIN,South Korea, April 3...

2023-04-03 16:47 3228

Harbour BioMed Reports Full Year 2022 Financial Results

CAMBRIDGE, Mass., SUZHOU, China and ROTTERDAM, Netherlands, April 3, 2023 /PRNewswire/ -- Harbour BioMed ("HBM" or the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeutics focusing on immune-oncolo...

2023-04-03 15:10 4505

The World's Second Approved Biosimilars of Denosumab (MAILISHU)

SHANGHAI, April 3, 2023 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with the layout of whole industry chain, announced that the Denosumab solution for injection (trade name: MAILISHU, project code: 9MW0311), which is developed by its wholly-owned subsidiary T-m...

2023-04-03 13:44 2690

CBC Group Appoints Healthcare Veteran Abbas Hussain as Operating Partner

SINGAPORE, March 31, 2023 /PRNewswire/ -- Singapore-headquartered asset management firm, CBC Group ("CBC"), is pleased to announce the appointment of healthcare industry veteran, Abbas Hussain, as Operating Partner. In this role, Abbas will closely partner with CBC's business teams to identify, ...

2023-04-01 10:00 5109

Henlius 2022 Annual Results: Significant Achievements in Commercialisation, Surged to RMB3.2 Billion in Revenues

SHANGHAI, April 1, 2023 /PRNewswire/ -- Henlius (2696.HK) announced its 2022 annual results. In 2022, Henlius' revenue reached aboutRMB3.2147 billion, representing an increase of 91.1% YoY, primarily due to sales revenue and licensing revenue generated by the successive commercialisation of vario...

2023-04-01 00:06 10937

I-Mab Provides Business and Corporate Updates and Reports Financial Results for the Year Ended December 31, 2022

* Strategic reprioritization of the Company's pipeline to focus on key clinical assets and overall streamlining of corporate structure and workforce, resulting in a significant reduction in the cash burn rate and in significant pipeline achievements by focus * Thirteen key clinical milestones...

2023-03-31 18:30 5226

Boao Forum for Asia Enters the Healthcare Sector

Boao Lecheng International Medical Tourism Pilot Zone at Hainan Free Trade Port Helps China's Medical Sector Expand into Global Markets QIONGHAI, China, March 30, 2023 /PRNewswire/ -- Boao, the seaside resort and convention destination on the South China Sea coast, has again caught the attention...

2023-03-31 10:00 2290

Ablaze Pharmaceuticals Plans Development of Innovative GPC3 Targeted Radiopharmaceutical Therapy for Liver Cancer in Greater China

SHANGHAI, March 31, 2023 /PRNewswire/ -- Ablaze Pharmaceuticals, a biotech company that is focused on developing Targeted Radiotherapy (TRT) to benefit cancer patients inChina, today announced the development plans of a first-in-class novel peptide drug candidate against GPC3. The proprietary GPC...

2023-03-31 10:00 4747

Genscript Biotech Reports 2022 Annual Results*

Non-Cell Therapy Achieved 31.4% Adjusted Net Profit Growth Cell Therapy Business Revenue Surged By 70% * Revenue of the Group for the year ended December 31, 2022 was approximately US$625.7 million, representing an increase of 27.7% as compared with approximatelyUS$490.1 million for the year e...

2023-03-31 08:40 3999

Everest Medicines Announces Financial Results for Full Year Ended December 31, 2022

SHANGHAI, March 31, 2023 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on developing, manufacturing and commercializing transformative pharmaceutical products and vaccines, today announced its financial results for the full year...

2023-03-31 07:30 5610

Kintor Pharma Announces 2022 Annual Results and Recent Business Progress

SUZHOU, China, March 30, 2023 /PRNewswire/ -- Kintor Pharmaceutical Limited (Kintor Pharma, HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, today announced business highlights and financial results for the year ended31 Decembe...

2023-03-31 00:33 4278

Actinogen presents positive Phase 2a Xanamem data in at ADPD™ Alzheimer's and Parkinson's diseases conference

A longitudinal dataset indicating the utility of plasma pTau for patient selection in clinical trials of patients with mild Alzheimer's Disease (AD) and the likely therapeutic benefit of oral Xanamem in this population SYDNEY, March 30, 2023 /PRNewswire/ -- Actinogen Medical ASX: ACW ("ACW" or "...

2023-03-30 21:00 2880

ACROBiosystems' new strategic focus - streamlining the transition from preclinical development to commercialization

BASEL, Switzerland, March 30, 2023 /PRNewswire/ -- ACROBiosystems has begun to narrow its focus into helping accelerate the process between preclinical, clinical and commercialization. With over 10 years development, ACROBiosystems continues to surprise and bring new solutions to the pharmaceutic...

2023-03-30 20:51 3294

Turn Biotechnologies Introduces its Dermatology Platform to the European Aesthetic Community at AMWC

MOUNTAIN VIEW, Calif., March 30, 2023 /PRNewswire/ -- Turn Biotechnologies, a cell rejuvenation company developing novel mRNA medicines to cure untreatable, age-related conditions, announced that it will for the first time share new data for its revolutionary dermatology platform with the interna...

2023-03-30 20:00 4965

ACROBiosystems' new strategic focus - streamlining the transition from preclinical development to commercialization

NEWARK, Del., March 30, 2023 /PRNewswire/ -- With more than 10 years of experience in protein development, ACROBiosystems has continuously demonstrated its strength in developing products and services throughout the entire drug development process. As such, ACROBiosystems has begun to narrow its ...

2023-03-30 18:54 2674

DxVx Co., Ltd.'s affiliated company, Oxford Vacmedix (OVM) successfully completed Phase 1a in clinical trial of novel cancer vaccine OVM-200

SEOUL, South Korea, March 30, 2023 /PRNewswire/ -- DXVX announces that its affiliated company Oxford Vacmedix (OVM) has completed Phase 1a trial of cancer vaccine and plans to proceed Phase1b trial of OVM-200. DxVx Co., Ltd. is the Korean Stock market (KOSDAQ) listed company and is the largest s...

2023-03-30 17:39 3035

Great Place To Work unveils Best Workplaces in the Inaugural Singapore Healthcare and Biopharma List 2023

Employees express trust in leaders' competence and integrity and value fairness and impartiality as part of the workplace culture SINGAPORE, March 30, 2023 /PRNewswire/ -- Great Place To Work®, the global authority on workplace culture announced the 10 companies who are Best WorkplacesTM in its ...

2023-03-30 12:00 3419

ImmVira's oncolytic product MVR-C5252 targeting malignant glioma obtained NMPA's approval for Clinical Trial in China

SHENZHEN, China, March 29, 2023 /PRNewswire/ -- ImmVira announced that its oncolytic virus product MVR-C5252 targeting malignant glioma obtained the approval from National Medical Products Administration ("NMPA") for Phase I clinical trial inChina on March 29, 2023. Previously, MVR-C5252 also obt...

2023-03-30 08:00 2570
1 ... 246247248249250251252 ... 351

Week's Top Stories